Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 142Osteosarcoma 26Liposarcoma 25Leiomyosarcoma 25Histiocytoma, Malignant Fibrous 19Hemangiosarcoma 18Sarcoma, Synovial 17Neurofibrosarcoma 17Fibrosarcoma 17Rhabdomyosarcoma 16Dendritic Cell Sarcoma, Interdigitating 16Sarcoma, Ewing 13Neuroectodermal Tumors, Primitive, Peripheral 11HIV Infections 11Sarcoma, Kaposi 10Neoplasms 10Neoplasm Metastasis 10Malignant mesenchymal tumor 10Acquired Immunodeficiency Syndrome 10Lymphoma, Large B-Cell, Diffuse 9Dermatofibrosarcoma 9Ovarian Neoplasms 8Lymphoma 8Hemangiopericytoma, Malignant 8Desmoplastic Small Round Cell Tumor 8Sarcoma, Alveolar Soft Part 6Chondrosarcoma, Extraskeletal Myxoid 6Bone Neoplasms 6Chondrosarcoma 5Burkitt Lymphoma 5

Interventions

Temozolomide 1Methotrexate 1Irinotecan 1FANG vaccine 1Doxorubicin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Connective Tissue × Doxorubicin × Sarcoma × Clear all
NCT05057130 2024-04-01

Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

Blokhin's Russian Cancer Research Center

Phase 2/3 Unknown
50 enrolled
Sarcoma

Bone Neoplasms, Neoplasms, Connective Tissue, Sarcoma, Osteosarcoma, Neoplasms, Connective and Soft Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡